TY - JOUR
T1 - Breast cancer, neoadjuvant chemotherapy and residual disease
AU - Chávez-Macgregor, Mariana
AU - González-Angulo, Ana María
N1 - Funding Information:
Acknowledgments This work was supported in part by NCI 1K23CA121994-01 and The Susan G. Komen Foundation KG090341 (to AMG)
PY - 2010/7
Y1 - 2010/7
N2 - Neoadjuvant systemic therapy (NST) has become part of the standard treatment of patients with locally advanced breast cancer. Patients who achieve a pathologically complete response (pCR) after NST have improved outcomes compared with patients with residual disease at the primary tumor site or the lymph nodes. Achieving a pCR after NST correlates with improved disease-free and overall survival; therefore the amount of residual disease is a prognostic predictor, and it is an area of ongoing research. In this article, we review the literature on NST to highlight the importance of pCR as a prognostic indicator. We also review the definition of pCR and describe the association between different patient and tumor characteristics, including the breast cancer subtype classification, and its response to chemotherapy. We expand on the clinical impact of residual disease and comment on the importance of quantifying it and the current treatment recommendations for patients with residual disease after NST.
AB - Neoadjuvant systemic therapy (NST) has become part of the standard treatment of patients with locally advanced breast cancer. Patients who achieve a pathologically complete response (pCR) after NST have improved outcomes compared with patients with residual disease at the primary tumor site or the lymph nodes. Achieving a pCR after NST correlates with improved disease-free and overall survival; therefore the amount of residual disease is a prognostic predictor, and it is an area of ongoing research. In this article, we review the literature on NST to highlight the importance of pCR as a prognostic indicator. We also review the definition of pCR and describe the association between different patient and tumor characteristics, including the breast cancer subtype classification, and its response to chemotherapy. We expand on the clinical impact of residual disease and comment on the importance of quantifying it and the current treatment recommendations for patients with residual disease after NST.
KW - Breast cancer
KW - Neoadjuvant chemotherapy
KW - Residual cancer burden
KW - Residual disease
UR - http://www.scopus.com/inward/record.url?scp=77956016989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956016989&partnerID=8YFLogxK
U2 - 10.1007/s12094-010-0538-0
DO - 10.1007/s12094-010-0538-0
M3 - Review article
C2 - 20615822
AN - SCOPUS:77956016989
SN - 1699-048X
VL - 12
SP - 461
EP - 467
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 7
ER -